We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,150

Federal Court of Appeal reinterprets product specificity requirements
  • Gowling Lafleur Henderson LLP
  • Canada
  • August 26 2015

On July 17 2015 the Federal Court of Appeal set aside a judgment of the Federal Court that upheld Health Canada's refusal to list Canadian Patent 2


Teva v Pfizer, or the “Viagra saga”: if there is no quid proper disclosure there can be no quo exclusive monopoly rights
  • Fasken Martineau DuMoulin LLP
  • Canada
  • November 19 2012

Sildenafil is the active ingredient in Viagra, the blockbuster potency-enhancing drug marketed by Pfizer


Formulation patent found not to be infringed as a redacted excipient was not a “pentahydric or hexahydric alcohol”
  • Borden Ladner Gervais LLP
  • Canada
  • April 22 2015

Apotex has successfully alleged that Teva’s patent to “Stable Compositions Containing Rasagiline” will not be infringed by Apotex’s use of a


Patents found obvious; subsequent appeal moot
  • Norton Rose Fulbright Canada LLP
  • Canada
  • March 6 2015

Janssen Inc (Janssen) brought two Applications pursuant to section 6 of the Patented Medicines (Notice of Compliance) Regulations for orders


Pharma in brief - Federal Court of Appeal finds that “promised” utility need not be coterminous with the inventive concept
  • Norton Rose Fulbright Canada LLP
  • Canada
  • July 27 2015

AstraZeneca Canada Inc. (AstraZeneca) appealed from the decision of Justice Rennie of the Federal Court (reported as AstraZeneca Canada Inc. v


Pharma in brief - Federal Court of Appeal relaxes the “perfect match” requirement for patent listing under the Patented Medicines (Notice of Compliance) Regulations
  • Norton Rose Fulbright Canada LLP
  • Canada
  • July 28 2015

The Minister of Health refused to list a patent on the Patent Register in respect of a fixed-dose combination product because it did not contain a


Federal court overturns Commissioner of Patents: claims with fixed dosages and dosing schedules held not to be methods of medical treatment
  • Bereskin & Parr LLP
  • Canada
  • January 16 2015

In AbbVie Biotechnology Ltd v Canada (Attorney General) "AbbVie" the Federal Court allowed AbbVie's appeal of a decision by the Commissioner of


Listing patents against combination drugs in Canada ? Changes coming
  • Gowling Lafleur Henderson LLP
  • Canada
  • December 1 2014

On Nov. 26, 2014, Industry Canada announced an important proposed change to the eligibility requirements for listing a patent against a drug in


Canadian patent term extension is coming
  • Bereskin & Parr LLP
  • Canada, European Union
  • October 18 2013

Canada and Europe announced an agreement in principle on a Comprehensive Economic and Trade Agreement (“CETA”) that will potentially increase Canadian


Patent for esomeprazole tablets found not to be obvious
  • Norton Rose Fulbright Canada LLP
  • Canada
  • March 29 2013

AstraZeneca Canada Inc. and AstraZeneca AB (“AstraZeneca”) brought an application pursuant to section 6 of the Patented Medicines (Notice of